iRhythm Technologies

iRhythm Technologies (IRTC) announced a *Heart Rhythm* publication and new data at AHA 2025 regarding its Zio long-term continuous monitoring (LTCM) system. The *Heart Rhythm* study of over 1.1 million patients revealed that traditional 24-48 hour monitoring missed actionable arrhythmias in 64% of daily-symptom patients. AHA presentations showed high patient compliance with at-home Zio device application(>13.8 days wear time, >98% analyzable ECG). Analyses of >10 million patients indicated early arrhythmia emergence linked to chronic kidney disease, suggesting the need for earlier cardiac monitoring.